The Limited Times

Now you can see non-English news...

Covid-19: German CureVac abandons its first vaccine candidate

2021-10-12T13:44:59.396Z

The German laboratory CureVac announced on Tuesday the abandonment of the development of its first candidate vaccine against Covid-19, initially a carrier ...



The German laboratory CureVac announced Tuesday the abandonment of the development of its first candidate vaccine against Covid-19, initially hopeful but whose effectiveness has proved disappointing, to focus on a new, more promising serum.

The company specializing in messenger RNA will "

focus on the development of a vaccine against Covid-19 on the second generation

" on which it is working with the British GSK and will therefore "

withdraw

" the current candidate from the procedure continuous review by the European Medicines Agency (EMA).

Read alsoCovid-19: CureVac's vaccine candidate effective at only 48%

This "

puts an end

" to the pre-order agreement for 405 million doses with the European Union, specifies the laboratory, which however continues discussions with Brussels on the second generation of vaccine.

"

The global fight against Covid-19 continues and we are determined to make a decisive contribution to it with a safe and effective vaccine

" but "

the requirements for an effective fight against the virus and the variants that appear have changed

", explained Franz -Werner Haas, boss of CureVac, in a statement.

48% efficiency

The German laboratory announced in early July the final results of its large-scale clinical study which showed an efficacy of only 48%, a rate much lower than other mRNA vaccines from the Pfizer / BioNTech and Moderna alliance.

CureVac and GSK want to launch “

in the coming months

” the clinical study on the second-generation vaccine, which takes more into account the variants, for approval “in the

course of 2022

”.

An authorization for the first vaccine would also have been probable "

at the earliest in the second quarter

" of next year, the statement said.

Read alsoCovid-19: the vaccine of the German CureVac facing delays

"

We welcome the fact that CureVac is focusing on the promising second generation vaccine

", called CV2CoV, for which the first studies show "

a clear improvement

" compared to the first candidate, CVnCoV, affirms Rino Rappuoli, scientific director of GSK.

The biotech founded in 2000 by researcher Ingmar Hoerr, a pioneer in messenger RNA research, was among the first to embark on the vaccine race.

Source: lefigaro

All business articles on 2021-10-12

You may like

Trends 24h

Business 2021-12-02T05:12:08.226Z

Latest

© Communities 2019 - Privacy